Antitumor efficacy of AAV-mediated systemic delivery of interferon-beta (Q45885532)

17 December 2017

title

Antitumor efficacy of AAV-mediated systemic delivery of interferon-beta (English)

1 reference

17 December 2017

author name string

C J Streck

1

1 reference

17 December 2017

P V Dickson

2

1 reference

17 December 2017

C Y C Ng

3

1 reference

17 December 2017

J Zhou

4

1 reference

17 December 2017

M M Hall

5

1 reference

17 December 2017

J T Gray

6

1 reference

17 December 2017

A C Nathwani

7

1 reference

17 December 2017

A M Davidoff

8

1 reference

17 December 2017

publication date

1 January 2006

1 reference

17 December 2017

published in

Cancer Gene Therapy

1 reference

17 December 2017

volume

13

1 reference

17 December 2017

issue

1

1 reference

17 December 2017

page(s)

99-106

1 reference

17 December 2017

Virus interference. II. Some properties of interferon

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

Cytokines in cancer pathogenesis and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

How cells respond to interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

Interferon-alpha in tumor immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

Why do so many cancer patients fail to respond to interferon therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

Progress in antiangiogenic gene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

Restriction of neuroblastoma angiogenesis and growth by interferon-alpha/beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

Inhibition of the glioblastoma cell cycle by type I IFNs occurs at both the G1 and S phases and correlates with the upregulation of p21(WAF1/CIP1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

Interferon-beta gene therapy improves survival in an immunocompetent mouse model of carcinomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

Interferon-beta gene therapy for cancer: basic research to clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

Human and mouse IFN-beta gene therapy exhibits different anti-tumor mechanisms in mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

How does interferon work? Does it even matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

7 January 2021

Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

7 January 2021

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

7 January 2021

Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700878

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700878

1 reference

17 December 2017

Dimensions Publication ID

1031964590

0 references

Fatcat ID

release_irsigvpgobelvimff3wlas2s3a

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/irsigvpgobelvimff3wlas2s3a

24 November 2022

mapped directly with Wikidata item

1 reference

17 December 2017